LUCARG-39D is under clinical development by Legend Biotech and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase I drugs for Follicular Lymphoma have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LUCARG-39D’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LUCARG-39D overview
LUCAR-G39D is under development for the treatment of relapsed and refractory B-cell non-Hodgkin lymphoma, follicular lymphoma and diffuse large B-cell lymphoma. The therapeutic candidate comprises genetically modified T cells to express chimeric antigen receptors (CAR) targeting cells expressing CD19 and CD20. It is administered through parenteral route.
Legend Biotech overview
Legend Biotech, a subsidiary of Genscript Biotech Corp, is a commercial-stage biotechnology company. It primarily focuses on the development, manufacturing, and commercialization of novel cell therapies. The company’s main focus is on diseases considered intractable and incurable, such as hematological malignancies and solid tumors. Its product, CARVYKTI™ (ciltacabtagene autoleucel), is a cell therapy approved for use in specific medical conditions. Legend Biotech‘s therapies are designed for patients worldwide suffering from chronic and life-threatening diseases. The company operates in the Americas and Europe. Legend Biotech is headquartered in Somerset, New Jersey, the US.
For a complete picture of LUCARG-39D’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
